Biotechnology industry advocates warned that drug price controls resembling Most Favored Nation (MFN) policies could worsen affordability and access. In BIO’s March Coffee Chat, Karin Hoelzer, Senior Director of Patient Advocacy at BIO, argued that ongoing evidence from the Inflation Reduction Act’s out-of-pocket cap shows benefits are being offset by plan behavior, including higher premiums, reduced plan choices, and intensified formulary management. Hoelzer pointed to Medicare Access for Patients’ (MAPRx) report, “Inflation Reduction Act: Access Barriers Undermine Affordability,” which says early evidence suggests the out-of-pocket cap’s impact is increasingly offset by shifts in insurer utilization management. The concern extends to MFN-style approaches, which could import foreign pricing systems tied to health economics assumptions. The exchange matters for biotech because coverage design and access barriers can directly affect uptake of high-cost specialty drugs, including oncology and immunology therapies.